Background People who inject drugs (PWID) are at increased risk for HIV and hepatitis C
virus (HCV) infection and also have high levels of homelessness and unstable housing. We …

Background & Aims HCV reinfection following successful treatment can compromise
treatment outcomes. This systematic review assessed the rate of HCV reinfection following …

Objectives As overdose deaths from fentanyl continue to increase, optimizing use of
medications for opioid use disorder has become increasingly important. Buprenorphine is a …

Opioid use disorder (OUD) is a common, treatable chronic disease that can be effectively
managed in primary care settings. Untreated OUD is associated with considerable morbidity …

Background The COVID-19 pandemic led to an unprecedented relaxation of restrictions on
take-home doses in opioid agonist treatment (OAT). We conducted a mixed methods …

Abstract Background and Aims Although the Netherlands, Canada and Australia were early
adopters of harm reduction for people who inject drugs (PWID), their respective HIV and …

The COVID-19 pandemic triggered unprecedented expansion of telemedicine, including in
the delivery of opioid agonist treatment (OAT) for people with opioid use disorder (OUD) …

This paper is the forty-second consecutive installment of the annual anthological review of
research concerning the endogenous opioid system, summarizing articles published during …

Background Across different types of oral Opioid Agonist Treatment for people with Opioid
Use Disorder, receiving a dose that meets their needs is associated with better outcomes …

Background Opioid agonist treatments (OAT) are effective interventions for reducing illicit
opioid use; however, less is known about OAT among adolescents and young adults (AYA) …